Olmesartan Medoxomil/Hydrochlorothiazide Krka (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil/Hydrochlorothiazide Krka, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for systemic use. It is employed to treat hypertension in adult patients, often in combination with a thiazide diuretic to improve blood‑pressure control.

GNH USA supplies Olmesartan Medoxomil/Hydrochlorothiazide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company emphasizes quality assurance, regulatory compliance and reliable global logistics to ensure product integrity through validated manufacturing processes and continuous monitoring.

Olmesartan medoxomil/hydrochlorothiazide is indicated for the management of hypertension, a common cardiovascular condition.

Hypertension: reduces systolic and diastolic blood pressure, helping to lower the risk of cardiovascular events.

Adverse reactions reported with Olmesartan medoxomil/hydrochlorothiazide span a range of frequencies and severities.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Mild electrolyte disturbances (e.g., low potassium) - Gastrointestinal upset such as nausea or abdominal discomfort

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hypotension (excessively low blood pressure) - Acute renal impairment or failure - Hyperkalemia (elevated potassium levels) - Pancreatitis - Anaphylactic or severe allergic reactions

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: ensure adequate control and avoid excessive lowering. - Renal function assessment: check serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolyte surveillance: monitor potassium and sodium levels during diuretic therapy. - Hepatic impairment: use with caution in patients with liver dysfunction. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxomil/hydrochlorothiazide may interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Aliskiren (combined use can increase risk of renal impairment and hyperkalemia). - Potassium‑sparing diuretics (may cause dangerous hyperkalemia). - NSAIDs (can attenuate antihypertensive effect and affect renal function). - Lithium (increased lithium toxicity). - ACE inhibitors (heightened risk of hyperkalemia and renal dysfunction).

Moderate Interactions (Monitor Closely): - Other antihypertensives (additive blood‑pressure lowering effect). - Loop or thiazide diuretics (potassium balance may shift). - Antidiabetic agents (blood‑glucose control may be altered). - CYP450 inhibitors (potentially affect olmesartan metabolism). - Oral contraceptives (may raise blood pressure).